More promising results are expected from another multicenter clinical trial conducted in Australia (ACTRN12621000171819), which is investigating the role of [89Zr]Zr-durvalumab PET in characterizing PD-L1 expression in patients with NSCLC treated with chemoradiotherapy [32]. Here, CD274 is linked to non-small cell lung carcinoma.